Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

Bibliographic Details
Main Authors: Liu, Xiaoqun, Liu, Xiangdong, Qiao, Tiankui, Chen, Wei, Yuan, Sujuan
Format: Online
Language:English
Published: Dove Medical Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938144/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938144/

Similar Items